Results Among 490 patients included in the primary analysis (mean [SD] age, 62.5 [8.7] years; 267 women [54.5%]), 52 of 241 patients (21.6%) in the ivermectin group and 43 of 249 patients (17.3%) in the control group progressed to severe disease (relative risk [RR], 1.25; 95% CI, 0.87-1.80; P = .25). For all prespecified secondary outcomes, there were no significant differences between groups. Mechanical ventilation occurred in 4 (1.7%) vs 10 (4.0%) (RR, 0.41; 95% CI, 0.13-1.30; P = .17), intensive care unit admission in 6 (2.4%) vs 8 (3.2%) (RR, 0.78; 95% CI, 0.27-2.20; P = .79), and 28-day in-hospital death in 3 (1.2%) vs 10 (4.0%) (RR, 0.31; 95% CI, 0.09-1.11; P = .09). The most common adverse event reported was diarrhea (14 [5.8%] in the ivermectin group and 4 [1.6%] in the control group).“
GUYS AND GALS READ THE STUDY!!!!
Ivermectin cut the death rate by 69 percent!! 3 deaths for Ivermectin versus 10 for standard care!! So absurd to claim the study was about “progression to severe disease” ? Isn’t death a sign of severe disease?
brookwood wrote: “”GUYS AND GALS READ THE STUDY!!!!
Ivermectin cut the death rate by 69 percent!! 3 deaths for Ivermectin versus 10 for standard care!! So absurd to claim the study was about “progression to severe disease” ? Isn’t death a sign of severe disease?””
Yes, by all means, read the study:
“Before the trial started, the case fatality rate in Malaysia from COVID-19 was about 1%,25 a rate too low for mortality to be the primary end point in our study. Even in a high-risk cohort, there were 13 deaths (2.7%). A recent meta-analysis of 8 randomized clinical trials of ivermectin to treat SARS-CoV-2 infection, involving 1848 patients with 71 deaths (3.8%), showed that treatment with the drug had no significant effect on survival.26”